Abstract:Background/Aims: Evidence suggests that IL-6 affects bone mass by modulating osteocyte communication towards osteoclasts. However, the mechanism by which IL-6 enhances osteocyte-mediated osteoclastogenesis is unclear. We aimed to investigate the inflammatory factors in serum after orthodontic surgery and their relationship between osteocytes and osteoclasts. Methods: Serum was obtained from 10 orthognathic surgery patients, and inflammatory factors were detected by ELISA. We treated the osteocyte-like cell line MLO-Y4 with recombinant mouse IL-6 and IL-6 receptor (IL-6R), and used quantitative RT-PCR and Western blotting to explore Receptor activator of nuclear factor-κB ligand (RANKL) expression at both the mRNA and protein level. MLO-Y4 cells were co-cultured with osteoclast precursor cells, and the formation of osteoclasts was detected by tartrate-resistant acid phosphatase (TRAP) staining. To explore the role of JAK2 in the osteocyte-mediated osteoclastogenesis, AG490, a JAK2 inhibitor, was used to inhibit the JAK2-STAT3 pathway in osteocytes. Results: In our study, we found that IL-6 and RANKL were stimulated in serum 3-7 days after orthognathic surgery. Therefore, IL-6 and IL-6 receptor enhanced the expression of RANKL at both the mRNA and protein level in MLO-Y4. Furthermore, when MLO-Y4 cells were co-cultured with osteoclast precursor cells, it significantly stimulated osteoclastogenesis. Our study indicated that osteocytes could promote osteoclastic differentiation and the formation of TRAP-positive multinucleated cells after stimulation with IL-6 and IL-6R. Our results also indicated that treatment with IL-6 and IL-6R increased RANKL mRNA expression and the RANKL/OPG expression ratio. Meanwhile, the phosphorylation of Janus kinase 2 (JAK2) and Signal transducer and activator of transcription (STAT3) also correlated with RANKL levels. Furthermore, we investigated the effects of a specific JAK2 inhibitor, AG490, on the expression of RANKL in osteocyte-like MLO-Y4 cells and osteocyte-mediated osteoclastogenesis. The results showed that AG490 inhibited (p)-JAK2 and RANKL expression. Osteoclastic differentiation was decreased after pretreatment in MLO-Y4 with mouse IL-6/IL-6R and AG490; therefore, we concluded that IL-6 increased osteocyte-mediated osteoclastic differentiation by activating JAK2 and RANKL. Conclusion: The effects of IL-6/il-6R and AG490 on osteocyte-mediated osteoclastogenesis contribute to our understanding of the role of inflammatory factors in the interaction between osteocytes and osteoclast precursors. IL-6 and RANKL are key factors for bone remodelling after the orthodontic surgery, and their roles in bone remodelling may be fundamental mechanisms accelerating tooth movement by orthodontic surgery.

IL-6 Promotes Low Concentration of RANKL-induced Osteoclastic Differentiation by Mouse BMMs Through Trans-Signaling Pathway

Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways

Combination Of Il-6 And Sil-6r Differentially Regulate Varying Levels Of Rankl-Induced Osteoclastogenesis Through Nf-Kappa B, Erk And Jnk Signaling Pathways

TRAF6/ERK/p38 Pathway is Involved in Interleukin-17-mediated Autophagy to Promote Osteoclast Precursor Cell Differentiation.

Mineralizing Solution and Dexamethasone Enhance Receptor Activator for NF-κB Ligand Expression in Rat Bone Marrow Stromal Cells

Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells

IL-1R/TLR2 Through MyD88 Divergently Modulates Osteoclastogenesis Through Regulation of Nuclear Factor of Activated T Cells C1 (nfatc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1)

IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro

Synergy Between IL-6 and Soluble IL-6 Receptor Enhances Bone Morphogenetic Protein-2/Absorbable Collagen Sponge-Induced Bone Regeneration Via Regulation of BMPRIA Distribution and Degradation.

Osteocytes Regulate Osteoblast Differentiation and Osteoclast Activity Through Interleukin-6 under Mechanical Loading

Interleukin‐4 Inhibits RANKL‐induced NFATc1 Expression Via STAT6: A Novel Mechanism Mediating Its Blockade of Osteoclastogenesis

Molecular Basis of Requirement of Receptor Activator of Nuclear Factor Κb Signaling for Interleukin 1-Mediated Osteoclastogenesis.

IL-6 potentiates BMP-2-induced osteogenesis and adipogenesis via two different BMPR1A-mediated pathways

Class A Scavenger Receptor Exacerbates Osteoclastogenesis by an Interleukin-6-Mediated Mechanism through ERK and JNK Signaling Pathways

RANKL expression of primary osteoblasts is enhanced by an IL-17-mediated JAK2/STAT3 pathway through autophagy suppression

Interleukin-6 Induces Immunometabolic Reprogramming In Human Rheumatoid Arthritis Synovial Fibroblasts To Promote Osteoclastogenesis

RANKL Downregulates Cell Surface CXCR6 Expression Through JAK2/STAT3 Signaling Pathway During Osteoclastogenesis

C-C Chemokine Receptor Type 6 Modulates the Biological Function of Osteoblastogenesis by Altering the Expression Levels of Osterix and OPG/RANKL

Effects of interleukin‐7/interleukin‐7 receptor on RANKL‐mediated osteoclast differentiation and ovariectomy‐induced bone loss by regulating c‐Fos/c‐Jun pathway

IL-6 Alters Osteocyte Signaling toward Osteoblasts but Not Osteoclasts

Il-1 Mediates Tnf-Induced Osteoclastogenesis